HER2 Breast Cancer
Advertisement
Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest.
Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
TILs can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who can reduce adjuvant therapy.
Aliya Omer, AstraZeneca, talks about data that backs the efficacy of olaparib in treating high-risk early breast cancer.
In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death.
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.